HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES
Details
Publication Year 2024-08-20,Volume 5,Issue #8,Page 101644
Journal Title
Cell Reports Medicine
Publication Type
Research article
Abstract
HSD3B1 encodes 3β-hydroxysteroid dehydrogenase-1, which converts adrenal dehydroepiandrosterone to 5α-dihydrotestosterone and is inherited in adrenal-permissive (AP) or adrenal-restrictive forms. The AP allele is linked to castration resistance, mainly in low-volume tumors. Here, we investigate the association of HSD3B1 alleles with outcomes in ARCHES, a multinational, double-blind, randomized, placebo-controlled phase 3 trial that demonstrated clinical benefit with enzalutamide plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) compared to those treated with placebo plus ADT. There are no significant differences between genotypes for clinical efficacy endpoints. Enzalutamide significantly improves radiographic progression-free survival and overall survival vs. placebo irrespective of HSD3B1 status. Men with the AP genotype have higher post-progression mortality and treatment-emergent adverse events, including hypertension, cardiovascular events, and gynecomastia, but a lower fracture rate. Overall, enzalutamide is beneficial in men with mHSPC independent of the HSD3B1 genotype. Inherited polymorphisms of HSD3B1 may account for differential toxicities.
Publisher
Elsevier
Keywords
Humans; Male; *Phenylthiohydantoin/therapeutic use; *Nitriles/therapeutic use; *Benzamides/therapeutic use; *Progesterone Reductase/genetics/metabolism; *Androgen Antagonists/therapeutic use; *Genotype; *Steroid Isomerases/genetics; *Multienzyme Complexes/genetics; Treatment Outcome; Aged; Prostatic Neoplasms/genetics/drug therapy/pathology; Neoplasm Metastasis; Double-Blind Method; Middle Aged; Alleles; Hsd3b1; androgens; enzalutamide; metabolism; metastatic hormone-sensitive prostate cancer
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1016/j.xcrm.2024.101644
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-19 04:50:56
Last Modified: 2024-09-19 04:57:04

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙